CNBX Pharmaceuticals Inc.
CNBX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$160.58K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $160,577.00 |
|---|---|
| Enterprise Value | $271,090.00 |
| Earnings per Share | $0 |
| Beta | 0.81 |
| Outstanding Shares | 1,318,594,182 |
Return
| Return on Equity | 17.37% |
|---|---|
| Return on Assets | -3611.50% |
| Return on Invested Capital | 16.23% |
Valuation & Multiples
| P/E Ratio | -0.5 |
|---|---|
| PEG | -0.32 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.63 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.44 |
| Debt to Equity | -0.05 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About CNBX Pharmaceuticals Inc.
1 employees
CEO: Eyal Barad
CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule fo...